Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
Part of paid clinical trials in Salt Lake City, Utah.
- Sponsor
- University of Utah
- Study ID
- NCT02200562
- Phase
- PHASE1
- Status
- Terminated
Conditions
- Stage III or IV Melanoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ipilimumab and dabrafenib — DRUG
Study Details
Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment in Stage III or IV melanoma. Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control rates.
Key Dates
- Start date
- Dec 31, 2014
- Status verified
- Feb 2017
- Primary completion
- Jan 20, 2017
- Completion
- Jan 20, 2017
Study Design
- Enrollment
- 6 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Ipilimumab and Dabrafenib
Primary Outcome Measure
Safety of ipilimumab and dabrafenib in combination [ Time Frame: Safety analysis will be measured based on frequency and severity of adverse events experienced by patients during the study treatment period which is expected to last about 24 weeks. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | - |
Find similar trials in Salt Lake City, UT
By research site